CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $23.12M, above the global median of $16.24M
- FinancialsAltman Z-Score 12.31: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.86%Above 5Y avg (0.70%)
Annual Rate
CNY 0.15Paid annual
Payout Ratio
19.6%Sustainable
Last Ex-Dividend
Jun 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.44BCNY510.69M · vs all stocks (USD)
Trailing P/E
35.41xRevenue (TTM)
670.32MCNY99.41M · vs all stocks (USD)
Profit Margin
13.94%Beta
0.3450xvs all stocks
52-Week Change
-32.60%vs all stocks
Market Capitalization
3.44BCNY510.69M · vs all stocks (USD)
Enterprise Value
2.55BCNY378.62M · vs all stocks (USD)
Trailing P/E
35.41xForward P/E
26.56xPrice to Sales (TTM)
5.14xPrice to Book (MRQ)
3.85xEnterprise to Revenue
3.81xEnterprise to EBITDA
29.67xGross Margin
82.48%Profit Margin
13.94%Operating Margin
13.35%Return on Assets (TTM)
4.05%Return on Equity (TTM)
11.69%Revenue (TTM)
670.32MCNY99.41M · vs all stocks (USD)
Revenue per Share (TTM)
3.67CNYUpdated Aug 19, 2026Quarterly Revenue Growth
22.90%Gross Profit (TTM)
554.41MCNY82.22M · vs all stocks (USD)
EBITDA (TTM)
88.44MCNY13.12M · vs all stocks (USD)
Net Income (TTM)
93.44MCNY13.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.50%Operating Cash Flow (TTM)
172.22MCNY25.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
155.91MCNY23.12M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.86%vs all stocks
5-Year Average Dividend Yield
0.70%vs all stocks
Payout Ratio
19.61%Revenue
636.27MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
113.81MCNYFY2025 · Dec 31, 2025Gross Profit
522.46MCNYFY2025 · Dec 31, 2025Operating Income
98.60MCNY14.62M · vs all stocks (USD)
Pre-tax Income
113.67MCNYFY2025 · Dec 31, 2025Income Tax Expense
20.55MCNYFY2025 · Dec 31, 2025Net Income
93.12MCNYFY2025 · Dec 31, 2025EBIT
114.67MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
135.57MCNYFY2025 · Dec 31, 2025Research & Development
14.67MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
346.86MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
444.92KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5000CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
185.16MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
185.16MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
93.12MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-543.38KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
99.22MCNYFY2025 · Dec 31, 2025Free Cash Flow
90.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
537.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
93.12MCNYFY2025 · Dec 31, 2025Other Non-cash Items
120.42KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
26.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.57MCNYFY2025 · Dec 31, 2025Capital Expenditures
-8.35MCNYFY2025 · Dec 31, 2025Purchase of Investments
-714.00MCNYFY2025 · Dec 31, 2025Sale of Investments
717.50MCNYFY2025 · Dec 31, 2025Other Investing Activity
3.01MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.84MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
22.11MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-33.66MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-23.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
24.51MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-10.88MCNYFY2025 · Dec 31, 2025Shares Outstanding
190.68MSharesUpdated Aug 19, 2026Float Shares
119.36MSharesUpdated Aug 19, 2026% Held by Insiders
36.04%vs all stocks
% Held by Institutions
3.89%vs all stocks
Total Cash (MRQ)
633.56MCNY93.96M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.55CNYUpdated Aug 19, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xCurrent Ratio (MRQ)
2.78xBook Value per Share (MRQ)
4.69CNYUpdated Aug 19, 2026Total Assets
1.02BCNY150.92M · vs all stocks (USD)
Total Current Assets
633.68MCNYFY2025 · Dec 31, 2025Total Liabilities
201.65MCNYFY2025 · Dec 31, 2025Total Non-current Assets
383.99MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
4.97MCNYFY2025 · Dec 31, 2025Total Current Liabilities
196.68MCNYFY2025 · Dec 31, 2025Cash
537.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
537.66MCNYFY2025 · Dec 31, 2025Accounts Receivable
12.74MCNYFY2025 · Dec 31, 2025Inventory
59.78MCNYFY2025 · Dec 31, 2025Accounts Payable
105.83MCNYFY2025 · Dec 31, 2025Short-term Debt
11.26MCNYFY2025 · Dec 31, 2025Other Current Liabilities
253.51KCNYFY2025 · Dec 31, 2025Common Stock (Book)
190.68MCNYFY2025 · Dec 31, 2025Retained Earnings
404.68MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
816.02MCNY121.02M · vs all stocks (USD)
Treasury Stock
48.15MCNYFY2025 · Dec 31, 202552-Week Low
14.65CNYUpdated Aug 19, 202652-Week High
26.83CNYUpdated Aug 19, 202652-Week Change
-32.60%vs all stocks
Beta
0.3450xvs all stocks
50-Day MA
16.54CNYUpdated Aug 19, 2026200-Day MA
18.71CNYUpdated Aug 19, 2026Avg 10-Day Volume
6.57MSharesUpdated Aug 19, 2026Avg 30-Day Volume
5.26MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.5100CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.31: safe zoneNotable
Altman Z-Score: 12.31
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $23.12M, above the global median of $16.24MNotable
Levered free cash flow (USD): 23,121,246.566Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Valneva SE
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule